181 related articles for article (PubMed ID: 38302968)
21. Elevated postoperative carcinoembryonic antigen guides adjuvant chemotherapy for stage II colon cancer: a multicentre cohort retrospective study.
Pu H; Yang W; Liu M; Pang X; Chen Y; Xiong Q
Sci Rep; 2024 Mar; 14(1):6889. PubMed ID: 38519578
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation value of preoperative peripheral blood lymphocyte-to-monocyte ratio on the prognosis of patients with stage III colon cancer].
Chen J; Peng J; Fan W; Zhang R; Wang F; Zhou W; Xu D; Pan Z; Lu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):73-78. PubMed ID: 30703797
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer.
Cakar B; Varol U; Junushova B; Muslu U; Gursoy Oner P; Gokhan Surmeli Z; Cirak Y; Karaca B; Sezgin C; Karabulut B; Uslu R
J BUON; 2013; 18(2):372-6. PubMed ID: 23818348
[TBL] [Abstract][Full Text] [Related]
24. Lymphovascular invasion represents a superior prognostic and predictive pathological factor of the duration of adjuvant chemotherapy for stage III colon cancer patients.
Zhang L; Deng Y; Liu S; Zhang W; Hong Z; Lu Z; Pan Z; Wu X; Peng J
BMC Cancer; 2023 Jan; 23(1):3. PubMed ID: 36593480
[TBL] [Abstract][Full Text] [Related]
25. The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency.
Yunlong W; Tongtong L; Hua Z
Cancer Med; 2023 Feb; 12(3):2440-2452. PubMed ID: 35904113
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.
Baxter NN; Kennedy EB; Bergsland E; Berlin J; George TJ; Gill S; Gold PJ; Hantel A; Jones L; Lieu C; Mahmoud N; Morris AM; Ruiz-Garcia E; You YN; Meyerhardt JA
J Clin Oncol; 2022 Mar; 40(8):892-910. PubMed ID: 34936379
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer.
Verhoeff SR; van Erning FN; Lemmens VE; de Wilt JH; Pruijt JF
Int J Cancer; 2016 Jul; 139(1):187-93. PubMed ID: 26914273
[TBL] [Abstract][Full Text] [Related]
28. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
[TBL] [Abstract][Full Text] [Related]
29. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
30. Choosing the Appropriate Individualized Adjuvant Chemotherapy in Stage III Colon Cancer Patients Under and Over 70 Years.
Taha HF; Harb OA; Gertallah LM; Abdelaziz LA
J Gastrointest Cancer; 2022 Sep; 53(3):581-591. PubMed ID: 34282542
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of high-risk factors and
Zhang Y; Wu Z; Zhang B; Hu H; Zhang J; Chen Y; Ding M; Cao Y; Deng Y
Ann Transl Med; 2022 Jun; 10(12):702. PubMed ID: 35845506
[TBL] [Abstract][Full Text] [Related]
32. Preoperative Strategies for Locally Advanced Colon Cancer.
Nair KG; Kamath SD; Chowattukunnel N; Krishnamurthi SS
Curr Treat Options Oncol; 2024 Mar; 25(3):376-388. PubMed ID: 38349502
[TBL] [Abstract][Full Text] [Related]
33. Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy.
Zhao F; Li E; Shen G; Dong Q; Ren D; Wang M; Zhao Y; Liu Z; Ma J; Xie Q; Liu Z; Li Z; Gao L; Zhao J
J Gastroenterol; 2023 Jul; 58(7):622-632. PubMed ID: 37036516
[TBL] [Abstract][Full Text] [Related]
34. Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study.
Lau D; Kalaitzaki E; Church DN; Pandha H; Tomlinson I; Annels N; Gerlinger M; Sclafani F; Smith G; Begum R; Crux R; Gillbanks A; Wordsworth S; Chau I; Starling N; Cunningham D; Dhillon T
ESMO Open; 2020 Feb; 5(1):. PubMed ID: 32079623
[TBL] [Abstract][Full Text] [Related]
35. Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer.
Shaib WL; Zakka KM; Jiang R; Yan M; Alese OB; Akce M; Wu C; Behera M; El-Rayes BF
Cancer; 2020 Sep; 126(18):4136-4147. PubMed ID: 32697360
[TBL] [Abstract][Full Text] [Related]
36. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
Yothers G; O'Connell MJ; Lee M; Lopatin M; Clark-Langone KM; Millward C; Paik S; Sharif S; Shak S; Wolmark N
J Clin Oncol; 2013 Dec; 31(36):4512-9. PubMed ID: 24220557
[TBL] [Abstract][Full Text] [Related]
37. Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study.
Artac M; Turhal NS; Kocer M; Karabulut B; Bozcuk H; Yalcin S; Karaagac M; Gündüz S; Isik N; Uygun K
Tumori; 2014; 100(2):143-8. PubMed ID: 24852857
[TBL] [Abstract][Full Text] [Related]
38. Controversial Issues Regarding Obligatory Adjuvant Chemotherapy for Stage IIIA Colon Cancer.
Kim CW; Kim TW; Lee JL; Park IJ; Yoon YS; Lim SB; Yu CS; Kim JC
Clin Colorectal Cancer; 2020 Dec; 19(4):e157-e163. PubMed ID: 32896486
[TBL] [Abstract][Full Text] [Related]
39. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
40. Deficient mismatch repair as a prognostic marker in stage II colon cancer patients.
Gkekas I; Novotny J; Fabian P; Nemecek R; Palmqvist R; Strigård K; Pecen L; Svoboda T; Gurlich R; Gunnarsson U
Eur J Surg Oncol; 2019 Oct; 45(10):1854-1861. PubMed ID: 31186203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
